Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IGMSNASDAQ:MDGLNASDAQ:NBRVNASDAQ:TBPHNASDAQ:ZEAL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGMSIGM Biosciences$1.36+2.7%$1.23$0.92▼$22.50$81.29M0.48375,147 shs526,792 shsMDGLMadrigal Pharmaceuticals$298.49-0.6%$291.28$200.63▼$377.46$6.64B-1.05359,776 shs108,674 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/ATBPHTheravance Biopharma$11.19+1.2%$10.16$7.44▼$11.82$557.51M-0.02267,774 shs65,540 shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGMSIGM Biosciences0.00%+25.46%+9.27%+19.91%-78.99%MDGLMadrigal Pharmaceuticals0.00%-0.75%+8.90%-5.06%+9.87%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%TBPHTheravance Biopharma0.00%-0.31%+3.85%+32.52%+31.43%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGMSIGM Biosciences4.4239 of 5 stars3.04.00.04.61.93.30.6MDGLMadrigal Pharmaceuticals4.0879 of 5 stars3.40.00.04.62.23.30.6NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATBPHTheravance Biopharma2.0796 of 5 stars3.30.00.00.02.72.50.6ZEALZealand Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGMSIGM Biosciences 1.90Reduce$5.50305.90% UpsideMDGLMadrigal Pharmaceuticals 2.89Moderate Buy$420.6340.92% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ATBPHTheravance Biopharma 2.67Moderate Buy$16.6048.41% UpsideZEALZealand Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TBPH, IGMS, NBRV, MDGL, and ZEAL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $25.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$24.005/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.004/24/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGMSIGM Biosciences$2.68M30.22N/AN/A$0.82 per share1.65MDGLMadrigal Pharmaceuticals$317.38M20.88N/AN/A$34.59 per share8.63NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00TBPHTheravance Biopharma$65.27M8.57N/AN/A$3.57 per share3.13ZEALZealand Pharma A/S$46.54M17.59N/AN/A$3.38 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGMSIGM Biosciences-$195.79M-$3.27N/AN/AN/A-7,417.79%-317.97%-71.43%8/13/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ATBPHTheravance Biopharma-$56.42M-$1.18N/A31.96N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)ZEALZealand Pharma A/S-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/ALatest TBPH, IGMS, NBRV, MDGL, and ZEAL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/8/2025Q1 2025TBPHTheravance Biopharma-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGMSIGM BiosciencesN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/AZEALZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGMSIGM BiosciencesN/A5.715.71MDGLMadrigal Pharmaceuticals0.175.915.58NBRVNabriva Therapeutics0.120.850.52TBPHTheravance BiopharmaN/A4.774.77ZEALZealand Pharma A/S0.934.794.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGMSIGM Biosciences42.79%MDGLMadrigal Pharmaceuticals98.50%NBRVNabriva Therapeutics0.27%TBPHTheravance Biopharma99.10%ZEALZealand Pharma A/S1.73%Insider OwnershipCompanyInsider OwnershipIGMSIGM Biosciences57.00%MDGLMadrigal Pharmaceuticals21.50%NBRVNabriva Therapeutics1.63%TBPHTheravance Biopharma6.90%ZEALZealand Pharma A/S2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGMSIGM Biosciences19059.78 million25.70 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableTBPHTheravance Biopharma11050.00 million46.55 millionOptionableZEALZealand Pharma A/S35546.54 million45.51 millionNot OptionableTBPH, IGMS, NBRV, MDGL, and ZEAL HeadlinesRecent News About These CompaniesStock Movers: Sainsbury's, Zealand Pharma, Taylor WimpeyJuly 1, 2025 | bloomberg.comZealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for MoreJune 20, 2025 | biospace.comBPositive results for Zealand’s GLP-1/GLP-2 receptor dual agonist dapiglutideJune 20, 2025 | thepharmaletter.comTProthena to lay off majority of staff; Zealand shares obesity drug dataJune 20, 2025 | biopharmadive.comBZealand Pharma’s 46% Stock Slump Makes New Obesity Drug CriticalJune 20, 2025 | bloomberg.comZealand Pharma announces positive topline results from phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideJune 20, 2025 | pharmabiz.comPZealand’s GLP-2 candidate shows early weight loss resultsJune 18, 2025 | statnews.comSZealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeksJune 18, 2025 | fiercebiotech.comFZealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideJune 18, 2025 | globenewswire.comZealand Pharma increases its share capital as a result of the exercise of employee warrantsJune 6, 2025 | globenewswire.comZealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndromeJune 2, 2025 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMay 27, 2025 | globenewswire.comEuropean stocks close higher after Trump delays 50% tariffs on EU; Zealand Pharma pops 10%May 26, 2025 | msn.comLilly’s former small molecule head makes the leap to a rising biotech in obesityMay 22, 2025 | finance.yahoo.comLilly’s former small molecule head makes the leap to a rising biotech in obesityMay 22, 2025 | finance.yahoo.comZealand Pharma Appoints Chief Development OfficerMay 20, 2025 | contractpharma.comCZealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development OfficerMay 19, 2025 | globenewswire.comZealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is PriceyMay 16, 2025 | seekingalpha.comZealand Pharma announces closing of collaboration, license agreement with RocheMay 12, 2025 | medicaldialogues.inMZealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025May 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBPH, IGMS, NBRV, MDGL, and ZEAL Company DescriptionsIGM Biosciences NASDAQ:IGMS$1.36 +0.04 (+2.65%) Closing price 07/3/2025 03:45 PM EasternExtended Trading$1.34 -0.02 (-1.48%) As of 07/3/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Madrigal Pharmaceuticals NASDAQ:MDGL$298.48 -1.67 (-0.55%) Closing price 07/3/2025 03:39 PM EasternExtended Trading$298.48 0.00 (0.00%) As of 07/3/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Theravance Biopharma NASDAQ:TBPH$11.18 +0.14 (+1.22%) Closing price 07/3/2025 01:21 PM EasternExtended Trading$11.18 0.00 (0.00%) As of 07/3/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Zealand Pharma A/S NASDAQ:ZEALZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
